Medicare AdvantagePrior AuthMedium impact
Imdelltra (tarlatamab-dlle) (Revised)
Humana·FL, KY, SC · Oncology, Pulmonology·Medicaid
Effective date
Aug 28, 2024
We identified it
Jun 24, 2026
Summary
Humana has established a new prior authorization policy for Imdelltra (tarlatamab-dlle), a cancer drug used for extensive-stage small cell lung cancer after platinum-based chemotherapy failure. The policy requires prior authorization for Medicare and Medicaid patients in Florida, Kentucky, and South Carolina, with specific clinical criteria including disease progression documentation.
Action Required
Immediately: Billing team and oncology providers must obtain prior authorization before prescribing or billing for Imdelltra (tarlatamab-dlle) for Humana Medicare and Medicaid patients in Florida, Kentucky, and South Carolina. Ensure documentation shows extensive-stage small cell lung cancer diagnosis and disease progression on or after platinum-based chemotherapy. Visit www.humana.com/PAL for medical coding information and prior authorization requirements.